Lead-in and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)

Trial Profile

Lead-in and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Bortezomib (Primary) ; Clofarabine (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Etoposide (Primary) ; Ofatumumab (Primary) ; Pegfilgrastim (Primary) ; Rituximab (Primary) ; Vincristine (Primary)
  • Indications Acute lymphoblastic leukaemia; Burkitt's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Aug 2017 Planned End Date changed from 1 Sep 2025 to 1 Aug 2025.
    • 10 Aug 2017 Planned primary completion date changed from 1 Sep 2025 to 1 Aug 2025.
    • 10 Aug 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top